ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimabs Unique Mechanism of Action in the Treatment of Atopic Dermatitis

ASLNDelisted Stock  USD 0.60  0.03  4.76%   
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
SAN MATEO, Calif. and SINGAPORE, June 23, 2023 ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the publication of data from the Phase 1a single ascending dose study of eblasakimab, a monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, in Clinical Immunology, a bimonthly peer-reviewed journal, supporting

Read at finance.yahoo.com
Yahoo News
  

Aslan Pharmaceuticals Fundamental Analysis

We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Return On Equity

Return On Equity Comparative Analysis

Aslan Pharmaceuticals is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Aslan Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Aslan Pharmaceuticals Related Equities

LYRALyra Therapeutics   10.53   
0%
100.0%
ANEBAnebulo Pharmaceuticals   7.64   
0%
72.0%
TILInstil Bio   6.01   
0%
57.0%
CTMXCytomX Therapeutics   4.88   
0%
46.0%
ERASErasca   1.95   
0%
18.0%
CGEMCullinan Oncology   1.25   
0%
11.0%
AGIOAgios Pharm   0.97   
0%
9.0%
GPCRStructure Therapeutics   0.90   
0%
8.0%
IVAInventiva   0.77   
0%
7.0%
ASMBAssembly Biosciences   0.55   
5.0%
0%
ANTXAN2 Therapeutics   0.67   
6.0%
0%
ACHLAchilles Therapeutics   0.93   
8.0%
0%
MLYSMineralys Therapeutics,   2.49   
23.0%
0%
AVTEAerovate Therapeutics   2.67   
25.0%
0%
IOBTIO Biotech   4.44   
42.0%
0%
ADAGAdagene   6.01   
57.0%
0%
GLUEMonte Rosa   6.29   
59.0%
0%
CMPXCompass Therapeutics   6.79   
64.0%
0%
NAMSNewAmsterdam Pharma   8.56   
81.0%
0%
ACRVAcrivon Therapeutics,   9.66   
91.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Consideration for investing in Aslan Stock

If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Transaction History
View history of all your transactions and understand their impact on performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated